Metformin in Fibrocystic Changes of Breast

Phase 3

Recruiting

• Conditions: Fibrocystic Changes of the braest.; Disorder of breast, unspecified

• Registration Number: IRCT20100706004329N6
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 November 2018

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 148

Inclusion Criteria

Age of fertility
FCC diagnosis based on history, examination and ultrasound.

Exclusion Criteria

Menopause
Body mass index greater than 29.9 kg / m2
Use of hormonal medications (such as estrogen, progesterone, GnRH agonist, GnRH antagonist, clomiphene, tamoxifen, letrozole, danazol, contraceptive pills, progesterone IUDs, DHEA) and drugs that affect metabolic status, such as weight, glucose, and lipid-lowering agents During the study or three months before the study began
Hormonal disorders and metabolic diseases such as hypo or hyperthyroidism, metabolic syndrome, diabetes, severe hyperlipidemia, galactorrhea
Proven or suspected pregnancy and lactation during the intervention
Other medical conditions, such as cardiovascular disease, epilepsy, renal or hepatic disorders
Contraindications for metformin use (such as hypersensitivity to biguanides, acidemia, heart disease, alcohol consumption, gastroparesis, hepatic disease, hyperthyroidism or hypothyroidism, severe iron deficiency anemia, renal impairments)
History of unwanted and intolerable side effects of metformin (such as abdominal pain, chest pain, chills, cholestasis, diarrhea, dizziness, increased liver enzymes, severe headache, hepatitis, hypoglycemia, megaloblastic anemia, myalgia, nausea, Palpitations, rash, rash, vomiting)

Study & Design

• Study Type: interventional
• Study Design: Not specified